Home | Publications | Diseases place holder
place holder place holder

Diseases

World Market for Addiction Disorders 2005-2012, The

New Horizons in High-Profile Dependency Markets

Publication Date   December 2005
Publisher   Spectra Intelligence
Product Type   Report
Pages   81
ISBN Number   not applicable
Product Code   SPE002
Ask a question about this product?

Price £1,100.00

approximately: $1,634 | €1,294

Summary


Examines the market for addiction pharmacotherapies currently estimated at US$2 billion but forecast to increase 41% CAGR to US$2.9 billion by 2012. Drivers of growth include increasing global prevalence of alcohol, narcotic, and nicotine dependencies and premarket pharmacotherapies to treat methamphetamine, phencyclidine, and gambling addictions. With over 30 drug candidates in the pipeline for addiction disorders, medical therapies for these highly prevalent difficult-to-treat conditions are on course for dynamic change. This report comments on strategic and commercial issues that may affect current product positioning and discusses key compounds such as naltrexone reformulations, nicotine replacement therapies, and novel vaccine therapies that have the potential to create new market sectors and become high-value products over the next decade. The report also provides insights into forthcoming market dynamics and product sales to 2012 to enable the reader to make assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Click here to see sample pages from this report (PDF format)

REPORT HIGHLIGHTS AND KEY FINDINGS

  • The current market for addiction disorders is valued at US$2 billion, which is forecast to increase 41% CAGR to US$2.9 billion by 2012
  • Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
  • Review of epidemiological, aetiological, and demographic data for addiction disorders
  • Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
  • Sales estimates (US$) to 2012 for major therapy areas
  • Strategic insights for life-cycle optimization and product development
  • Critical evaluation of leading addiction pharmacotherapies
  • Emerging markets identified and sector analysis
  • Trend analysis of industry events and activities over past 2 years
  • Detailed R&D themes and clusters by addiction area
  • Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
  • High revenue-yielding prospects identified with projected sales estimations
  • R&D pipeline positioning for novel candidates
  • Market insights for product development and drug promotion

    WHAT CAN I LEARN FROM THIS REPORT?

    · Which addiction therapies are the current and potential future market leaders
    · Insights into the demographics and aetiology of addiction disorders
    · How companies are reformulating products for addiction indications
    · Which premarket addiction pharmacotherapies are identified as high-value products
    · Which companies are developing drugs for addiction disorders
    · Sales predictions to 2012 for addiction pharmacotherapies
    · What the likely impact of pipeline products will be on value growth of the addiction market over the next decade
    · Which addiction subsectors could be niche market opportunities
    · What the future outlook holds for addiction pharmacotherapies
    · Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
    · Which molecules and compounds are main R&D clusters for dependency disorders
    · Which of the pipeline candidates are top prospects in the addiction market over the next
    decade and to 2020
    Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered…

    REASONS TO PURCHASE THIS REPORT

    · Detailed survey and analysis of the current and future global addiction disorder market
    · Comprehensive update on key marketed products indicated for alcohol, opiate, and nicotine dependency disorders
    · Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
    · Market analysis and insight of key addiction pharmacotherapies and pipelines
    · Market value predictions of individual marketed products to 2012
    · Insight and trend analysis of pipeline products for addiction disorders
    · Review of promising pipeline products and potential market opportunities
    · Insight into potential high-revenue earning addiction pharmacotherapies
    · Illustrates unmet needs of current pharmacotherapies to treat addictions and underserved subsectors of addiction disorders
    · Provides extensive coverage of the R&D pipeline for addiction disorders
    · Illustrates research themes and clusters for addiction candidates differentiated by mechanism of action and efficacy
    · Provides leads for potential licensing opportunities

    COMPANIES MENTIONED IN REPORT

    ACRUX, ALKERMES, ALPHARMA, ASTRAZENECA, BIOTIE THERAPIES, BRISTOL-MYERS SQUIBB, BRITANNIA PHARMACEUTICALS, CATALYST PHARMA, CEPHALON, COLLEGIUM PHARMACEUTICALS, DRUG ABUSE SCIENCES, FOREST LABORATORIES, GLAXOSMITHKLINE, INTERVEXION THERAPEUTICS, LIPHA, MERCK, NABI PHARMACEUTICALS, NOVARTIS, PFIZER, SANOFI-AVENTIS, SCHERING-PLOUGH, SOMAXON PHARMACEUTICALS, TARGACEPT, TITAN PHARMACEUTICALS, XENOVA,

    • Content


    List of Tables

    List of Figures

    Executive Summary

    Objectives of the Report

    Research Methodology

    Chapter 1 Introduction to Addiction Disorders

    Addiction Disorders
    Incidence of Addiction Disorders
    Neurobiological Basis of Addiction
    Treatment Options

    Chapter 2 The Addiction Pharmacotherapy Market

    Addictions
    Market Overview for Addiction Disorders
    Market Forecasts by Therapeutic Area
    Alcohol Addiction
    Narcotic Addiction
    Tobacco Addiction
    Market Forecasts for Addiction Disorders
    Market Analysis of Drugs to Treat Addiction Disorders
    Alcohol Addiction
    Alcohol Addiction Pharmacotherapies
    Acamprosate (Campral) - Merck/Forest Laboratories
    Mechanisms of Action/Efficacy
    Sales Estimates for Campral
    Product Line Extension Possibilities
    Disulfiram (Antabuse) - Alpharma
    Mechanism of Action/Efficacy
    Sales Estimates for Disulfiram
    Naltrexone Hydrochlride
    Mechanisms of Action/Efficacy
    Reformulation - Vivitrex, Alkermes/Cephalon
    Sales Estimates for Naltrexone
    Pipeline Focus
    Naltrexone Depot - Drug Abuse Sciences, France
    Nalmefene - BioTie Therapies, Finland
    Alcohol Addiction - Market Insights and Future Considerations
    Narcotic Addiction Pharmacotherapeutics
    Cocaine Addiction
    Mechanisms of Action of Cocaine
    Future Therapeutics for Cocaine Addiction
    Vaccine Therapy Focus - Xenova
    COC-AB/DAS-431 - Drug Abuse Sciences
    Opiate Addiction
    Drug Substitute Therapies
    Subutex/Subroxone (Buprenorphine) - Schering-Plough/Reckitt Benckiser
    Mechanisms of Action/Efficacy
    Reformulation
    Sales Estimates
    Methadone
    Mechanisms of Action/Efficacy
    Sales Estimates
    Drugs to Control Opiate Withdrawal Symptoms
    Brittofex (Lofexidine) - Britannia Pharmaceuticals
    Mechanisms of Action/Efficacy
    Sales Estimates
    Naltrexone
    Potential Reformulation
    Future Drugs to Treat Opiate Addiction
    Probuphine - Titan Pharmaceuticals
    Buprenorphine Depot - Drug Abuse Sciences
    Narcotic Addiction - Market Insights and Future Considerations
    Emerging Drug Addiction Focus
    Methamphetamine/Phencyclidine Abuse and Dependency
    InterveXion Therapeutics
    Outlook for Pharmacotherapeutic Markets Related to Alcohol and Substance Abuse
    Nicotine Addiction
    Prevalence and Mortality Statistics
    Nicotine - Mechanism of Action
    Nicotine Dependency and Smoking Cessation
    Smoking and Health Consequences
    Healthcare Costs of Smoking Addiction
    Nicotine Addiction Pharmacotherapeutics
    Market Analysis of Smoking Cessation Pharmacotherapeutics
    Nicotine Replacement Therapies
    Nicorette/Nicotrol - Pfizer
    Sales Estimates
    NiQuitin/NicoDerm/Nicorette/Nicabate - GlaxoSmithKline
    Sales Estimates
    Nicotinell/Habitrol - Novartis
    Sales Estimates
    Other Smoking Cessation Pharmacotherapies
    Zyban (Bupropion) - GlaxoSmithKline
    Sales Estimates
    Future Drugs to Treat Nicotine Addiction
    Late-Stage Development Product Focus
    Rimonabant (Acomplia) - Sanofi-Aventis
    Varenicline - Pfizer
    Vaccine Focus
    NicVAX - Nabi Biopharmaceuticals
    TA-NIC - Xenova
    Nicotine Addiction - Market Insights and Future Considerations
    Drugs in the Pipe

    Chapter 3 Drugs in Research and Development

    Addiction Disorders: Drugs in Research and Development
    Research and Development Overview
    Gambling Addiction - An Emerging Research and Development Area
    Nalmefene - Somaxon Pharmaceuticals

    Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining

    Market Analysis and Therapy Forecasting
    Therapy Area Forecasts
    Comparative Analysis: Addiction Pharmacotherapies
    Prospect Mining
    Addiction Disorder Pharmacotherapy Prospects
    Therapy Area Forecasts 2012 and 2020

    Chapter 5 Report Synopsis

    Addictions - Key Data Points
    Reference Sources

    List of Tables

    Table 1.1 Neurotransmitter Systems Associated with Addiction
    Table 1.2 Drugs of Abuse and their Associations with Neurotransmitter Systems
    Table 2.1 Estimated Global Sales (US$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2004-
    Table 2.2 Physiological Consequences of the Disulfiram-Alcohol Reaction29 Table 2.3 Estimated Sales (US$) and Annual Growth (%) of Smoking Cessation Therapies, 2004-2012 Table 2.4 Drugs in Development for Nicotine Addiction, 2005 (partial) 57 Table 3.1 Drugs in Development for Alcohol and Narcotic Addictions, 2005
    Table 3.2 Drugs in Development for Nicotine Addiction, 2005
    Table 4.1 Estimated Global Sales (US$) and Growth Rate (%) for Addiction Pharmacotherapies, 2004-
    Table 4.2 Therapy Area Forecasts for the World Addiction Disorder Market, 2012 & 2020 (US$)

    List of Figures

    Figure 1.1 Prevalence of Alcohol, Smoking, and Illicit Drug Abuse in UK and US Populations, 2002-
    Figure 2.1 Estimated Sales (US$) of Addiction Drugs Segmented by Therapeutic Area, 2004-
    Figure 2.3 Estimated Global Sales (US$) of Leading Addiction Drugs by Therapy Area, 252005 &
    Figure 4.1 Addiction Pharmacotherapy Market Forecasts, 2005 & 2012 (US$)
    Figure 4.2 Comparative Analysis of Leading Addiction Pharmacotherapies, 2004-2012 (US$) Figure 4.3 Key Addiction Disorder Drug Prospects, 2005